Adoptive T Cell Therapy of Cancer

Overview

Journal Curr Opin Immunol

Publisher Elsevier

Specialty Allergy & Immunology

Date 2010 Feb 23

PMID 20171074

Citations 61

Authors

Malcolm K Brenner

Helen E Heslop

Affiliations

Soon will be listed here.

Abstract

Adoptive transfer of T cells specific for antigens expressed on tumor cells is an attractive strategy for producing targeted and long-lived anti-tumor activity. T cell therapies have shown activity in selected clinical applications but broader application is limited by inadequate persistence of transferred T cells and by tumor-evasion strategies. Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment.

Citing Articles

Role of T cells in cancer immunotherapy: Opportunities and challenges.

Ahmed H, Mahmud A, Siddiquee M, Shahriar A, Biswas P, Shimul M Cancer Pathog Ther. 2024; 1(2):116-126.

PMID: 38328405 PMC: 10846312. DOI: 10.1016/j.cpt.2022.12.002.

Current State of Cell Therapies for Breast Cancer.

Gautam N, Elleson K, Ramamoorthi G, Czerniecki B Cancer J. 2022; 28(4):301-309.

PMID: 35880940 PMC: 9336570. DOI: 10.1097/PPO.0000000000000607.

Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors.

Fogli L, Aurigemma R, Sommers C, Singh A, Bourcier K, Ernstoff M J Immunother Cancer. 2021; 9(7).

PMID: 34266886 PMC: 8286786. DOI: 10.1136/jitc-2021-003048.

Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

DeRenzo C, Gottschalk S Adv Exp Med Biol. 2020; 1257:109-131.

PMID: 32483735 PMC: 7385999. DOI: 10.1007/978-3-030-43032-0_10.

Estimating Residence Times of Lymphocytes in Ovine Lymph Nodes.

McDaniel M, Ganusov V Front Immunol. 2019; 10:1492.

PMID: 31379805 PMC: 6646577. DOI: 10.3389/fimmu.2019.01492.

References

Vera J, Brenner L, Gerdemann U, Ngo M, Sili U, Liu H . Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010; 33(3):305-15. PMC: 2946348. DOI: 10.1097/CJI.0b013e3181c0c3cb. View

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

Nishida T, Hudecek M, Kostic A, Bleakley M, Warren E, Maloney D . Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res. 2009; 15(14):4759-68. PMC: 2785487. DOI: 10.1158/1078-0432.CCR-09-0199. View

Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L . IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 2008; 113(5):1006-15. DOI: 10.1182/blood-2008-05-156059. View

Cheever M, Allison J, Ferris A, Finn O, Hastings B, Hecht T . The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-37. PMC: 5779623. DOI: 10.1158/1078-0432.CCR-09-0737. View

Johnson L, Morgan R, Dudley M, Cassard L, Yang J, Hughes M . Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114(3):535-46. PMC: 2929689. DOI: 10.1182/blood-2009-03-211714. View

van Loenen M, Hagedoorn R, Kester M, Hoogeboom M, Willemze R, Falkenburg J . Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res. 2009; 69(5):2034-41. DOI: 10.1158/0008-5472.CAN-08-2523. View

Park J, DiGiusto D, Slovak M, Wright C, Naranjo A, Wagner J . Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007; 15(4):825-33. DOI: 10.1038/sj.mt.6300104. View

Kershaw M, Westwood J, Parker L, Wang G, Eshhar Z, Mavroukakis S . A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006; 12(20 Pt 1):6106-15. PMC: 2154351. DOI: 10.1158/1078-0432.CCR-06-1183. View

10.

Sportes C, Hakim F, Memon S, Zhang H, Chua K, Brown M . Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med. 2008; 205(7):1701-14. PMC: 2442646. DOI: 10.1084/jem.20071681. View

11.

Pule M, Savoldo B, Myers G, Rossig C, Russell H, Dotti G . Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14(11):1264-70. PMC: 2749734. DOI: 10.1038/nm.1882. View

12.

Vago L, Perna S, Zanussi M, Mazzi B, Barlassina C, Lupo Stanghellini M . Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009; 361(5):478-88. DOI: 10.1056/NEJMoa0811036. View

13.

Reichert J, Rosensweig C, Faden L, Dewitz M . Monoclonal antibody successes in the clinic. Nat Biotechnol. 2005; 23(9):1073-8. DOI: 10.1038/nbt0905-1073. View

14.

Cohen C, Li Y, El-Gamil M, Robbins P, Rosenberg S, Morgan R . Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007; 67(8):3898-903. PMC: 2147081. DOI: 10.1158/0008-5472.CAN-06-3986. View

15.

De Angelis B, Dotti G, Quintarelli C, Huye L, Zhang L, Zhang M . Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009; 114(23):4784-91. PMC: 2786289. DOI: 10.1182/blood-2009-07-230482. View

16.

Till B, Jensen M, Wang J, Chen E, Wood B, Greisman H . Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112(6):2261-71. PMC: 2532803. DOI: 10.1182/blood-2007-12-128843. View

17.

Heemskerk B, Liu K, Dudley M, Johnson L, Kaiser A, Downey S . Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008; 19(5):496-510. PMC: 2656366. DOI: 10.1089/hum.2007.0171. View

18.

Gerdemann U, Christin A, Vera J, Ramos C, Fujita Y, Liu H . Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009; 17(9):1616-25. PMC: 2835253. DOI: 10.1038/mt.2009.140. View

19.

Rosenberg S, Restifo N, Yang J, Morgan R, Dudley M . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8(4):299-308. PMC: 2553205. DOI: 10.1038/nrc2355. View

20.

Quintarelli C, Vera J, Savoldo B, Giordano Attianese G, Pule M, Foster A . Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007; 110(8):2793-802. PMC: 2018664. DOI: 10.1182/blood-2007-02-072843. View